Avenue Capital Group
VC Fund
New York, United States
Avenue Capital Group is a VC fund in New York focused on Biotechnology and Health Care. Avenue Capital Group was founded in 1995 by Marc Lasry and Sonia E. Gardner. Pioneers in the distressed debt market, Mr. Lasry and Ms. Gardner have successfully invested in the public and private debt and equity securities of distressed companies across a variety of industries for over two decades.Headquartered in New York, with offices inLondon, Luxembourg, Munich, and nine offices throughout Asia, the firm manages assets valued at approximately $15.8 billion as of March 31, 2009. Avenue draws on the skills and experience of approximately 300 employees and its Senior Principals, Marc Lasry and Sonia E. Gardner, who have spent virtually their entire careers in the field of distressed investments.
- Total investments:
- 50
- Last investment:
- Lead investor:
- 82%
- Fund size:
- $1B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Avenue Capital Group invests in
Stages Avenue Capital Group invests in
Countries Avenue Capital Group invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Post-IPO Debt
- $7M–$40M
- Debt Financing
- $14M–$155M
- Venture - Series Unknown
- $10M–$250M
Investment Focus
Industry
- Biotechnology 14 (28%)
- Health Care 10 (20%)
- Medical Device 9 (18%)
- Medical 6 (12%)
- Sports 5 (10%)
Stage
- Post-IPO Debt 16 (32%)
- Debt Financing 11 (22%)
- Venture - Series Unknown 7 (14%)
- Series A 4 (8%)
- Private Equity 3 (6%)
Country
- United States 32 (64%)
- United Kingdom 4 (8%)
- China 2 (4%)
- India 1 (2%)
- Canada 1 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Anil Gorthy
Senior Portfolio Manager
|
Senior Portfolio Manager | Total investments: 0 | Find email | |
|
Dan Galanter
Senior Managing Director
|
Senior Managing Director | Total investments: 0 | Find email | |
Jeffrey Becker
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Marc Lasry
Chairman, Chief Executive Officer and Co-Founder
|
Chairman, Chief Executive Officer and Co-Founder | Total investments: 21 | Find email | |
Sonia Gardner
Co-Founder, President and Managing Partner
|
Co-Founder, President and Managing Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Silk is the leading platform to quickly move mission-critical data to the cloud and to keep it operating at performance standards on par with even the fastest on-prem environments. Silk works with global enterprise companies and cloud providers to ensure a seamless, efficient, and smooth migration process, followed by unparalleled performancespeeds for all data and applications in the cloud.The platform makes cloud environments run 10x faster and the entire application stack is more resilient to any infrastructure hiccups or malfunctions. Silk has offices in Israel and is headquartered in Needham, MA. For more information, visit https://silk.us/ | $45M / Venture - Series Unknown / Sep 23, 2026 | ||
| Founded by Pablo Borquez Schwarzbeck, a fourth-generation farmer, ProducePay is eliminating the economic and food waste caused by the volatile, opaque, and fragmented nature of today’s global fresh produce supply chain. The AgTech company’s Predictable Commerce Platform is giving growers and buyers greater control of their business by providingunprecedented access to each other, capital, trading, insights and greater supply chain visibility. Consumers receive fresher produce more efficiently, knowing it is grown and delivered in responsible ways. This transformational approach is unlocking economic value, and creating a more sustainable global fresh produce industry. | $140M / Venture - Series Unknown / Sep 01, 2026 | ||
| Citius Oncology is a biopharmaceutical company that develops and commercializes oncology therapies. The company specializes in targeted therapies for cancer treatment, with a focus on immune-based approaches. The company recently gained FDA approval for LYMPHIR™, a therapy for relapsed or refractory cutaneous T-cell lymphoma. | $25M / Post-IPO Debt / May 05, 2026 | ||
| Quartzy provides the only complete solution for lab management that includes the world’s most comprehensive catalog of more than 3M lab supplies and deals backed by 1,000's of top suppliers. Trusted by 200,000 scientists across 13,000 labs nationwide, Quartzy streamlines inventory and purchasing communications to save labs time and money. | $23M / Debt Financing / Apr 13, 2026 | ||
| Asian University Basketball League is a pioneering pan-regional basketball competition. | Series A / Apr 09, 2026 | ||
| Turn Therapeutics is a pharmaceutical company that is dedicated to reducing the human and economic costs of infection and skin disease. Turn Therapeutics was founded to reduce antibiotic resistance through best-in-class acute and chronic wound care products. The company's mission is to leverage expertise in drug delivery to create disruptiveproducts for high need indications.It was founded in 2015 and its headquarters is located in Calabasas, California. | $7M / Post-IPO Debt / Mar 24, 2026 | ||
Nitra
|
Nitra offers expense management software that integrates with the banks to provide innovative loan products. | $115M / Debt Financing / Mar 10, 2026 | |
| North Carolina Courage is a women's soccer team that competes in the National Women's Soccer League. The company's product line includes jerseys, hats, coats, tees, accessories, scarves, and other items. | $40M / Private Equity / Mar 04, 2026 | ||
| Humacyte develops products for vascular disease and replacement of anatomical conduits. It offers human tissue-based products for regenerative medicine and vascular surgery applications; off-the-shelf extracellular matrix tissue products, which are formed in vitro from banked vascular smooth muscle cells and then decellularized to eliminate therisk of rejection; and vascular grafts. | $77.5M / Post-IPO Debt / Dec 16, 2025 | ||
| Myomo, a medical technology company, develops Myoelectric prosthetic technology to powered bracing devices that restore an individual’s mobility. It offers Myomo mPower 1000, a portable lightweight functional arm brace for use in the home and in clinical settings, which restores movement to a weakened arm as a result of neuromuscular damage causedor due to brain injury, including stroke, spinal cord injury, multiple sclerosis, cerebral palsy, muscular dystrophy, and traumatic brain injury. The company also provides PERL (Push, Eat, Reach, Lift) technique, a set of research-based treatment plans that integrate the mPower 1000 into functional repetitive task practice programs aiming to increase the functional activity; myGames, a virtual reality-based therapeutic training system to encourage brain-injured patients with upper limb motor disorders to practice physical exercises; and myProgress, an Android-based connected health platform that tracks and measures progress while using the mPower 1000. Its mobility system is designed to enable individuals to self-initiate and control the movement of partially paralyzed limbs using their own muscle signals. The company serves medical professionals, patients, and caregivers in the United States. Myomo, Inc. was formerly known as Active Joint Brace. The company was founded in 2004 and is based in Cambridge, Massachusetts. | $12.5M / Post-IPO Debt / Nov 04, 2025 | ||
| See all 50 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Avenue Capital Group invest in?
Avenue Capital Group invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Post-IPO Debt and Debt Financing stage. Most of the 50 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Avenue Capital Group's check size?
Avenue Capital Group typically joins rounds of $7M–$40M at Post-IPO Debt, $14M–$155M at Debt Financing and $10M–$250M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Avenue Capital Group participates in.
How do I contact Avenue Capital Group?
Public channels for Avenue Capital Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Avenue Capital Group?
The team at Avenue Capital Group includes Anil Gorthy (Senior Portfolio Manager), Dan Galanter (Senior Managing Director) and Jeffrey Becker (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
